Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Conjugate meningococcal vaccine filed by GSK

Conjugate meningococcal vaccine filed by GSK

2nd April 2007

Following successful trials in several African and Asian countries, GlaxoSmithKline (GSK) has announced that it has submitted its combination vaccine Globorix for approval by the European Medicines Agency (EMEA).

In addition to demonstrating a safe and effective immunity profile against meningococcal meningitis caused by Neisseria meningitides, the conjugate vaccine also was found to protect against five other major childhood diseases.

The submission of Globorix comes seven years after the World Health Organisation called for increased investment into the development of conjugation vaccines so as to provide a more cost-effective and long-term solution to the problem of meningitis in developing countries.

While current methods using polysaccharide vaccines are estimated to have saved the lives of around 70 per cent of those affected by one of the major meningitis epidemics, which occur every eight to 12 years within Africa’s “meningitis belt”, such methods offer protection to only infants aged three to five years.

“There is an urgent need for an improved meningococcal vaccine,” said Dr A Hodgson, director of the Navrongo Health Research Centre in Ghana.

“The filing of this new vaccine is good news for African infants because it means that state of the art vaccine technology is now one step closer to those who need it.”

According to GlaxoSmithKline, the vaccine could be available as early as 2008, with its licensing allowing it to be used exclusively outside of the European Union.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.